Aberrant methylation of the SLC22A18 promoter is one major mechanism responsible for the inactivation or downregulation of SLC22A18 in a number of tumor types, including breast [6], lung [5] and hepatoblastomas [8]. Here, SLC67A1 is linked to neoplasm.